XENE · Xenon Pharmaceuticals Inc.

0001193125-26-152834

Summary

Xenon Pharmaceuticals Inc. amended its 2025 Inducement Equity Plan on April 7, 2026, increasing the common stock reserve from 900,000 to 1,175,000 shares for employee inducement awards without shareholder approval.

Key takeaways

Amended 2025 Inducement Plan effective April 7, 2026.
Increased share reserve from 900,000 to 1,175,000 common shares.
For grants to new hires or rehired employees after bona fide interruption.
Awards limited to nonstatutory stock options, SARs, RSUs, restricted stock, performance awards.
Complies with Nasdaq Listing Rule 5635(c)(4); no shareholder approval sought.
Exhibit 10.1 contains full amended plan text.

Full analysis

The amendment expands the Company's capacity to issue equity incentives under the 2025 Inducement Plan specifically for attracting and retaining new or rehired employees, adding 275,000 shares to the reserve. This supports talent acquisition in a competitive biotech sector without requiring shareholder vote per Nasdaq rules. The plan authorizes various equity vehicles tailored as inducements, administered by the Compensation Committee.